Literature DB >> 19885876

Severe sepsis in cirrhosis.

Thierry Gustot1, François Durand, Didier Lebrec, Jean-Louis Vincent, Richard Moreau.   

Abstract

Sepsis is physiologically viewed as a proinflammatory and procoagulant response to invading pathogens. There are three recognized stages in the inflammatory response with progressively increased risk of end-organ failure and death: sepsis, severe sepsis, and septic shock. Patients with cirrhosis are prone to develop sepsis, sepsis-induced organ failure, and death. There is evidence that in cirrhosis, sepsis is accompanied by a markedly imbalanced cytokine response ("cytokine storm"), which converts responses that are normally beneficial for fighting infections into excessive, damaging inflammation. Molecular mechanisms for this excessive proinflammatory response are poorly understood. In patients with cirrhosis and severe sepsis, high production of proinflammatory cytokines seems to play a role in the worsening of liver function and the development of organ/system failures such as shock, renal failure, acute lung injury or acute respiratory distress syndrome, coagulopathy, or hepatic encephalopathy. In addition, these patients may have sepsis-induced hyperglycemia, defective arginine-vasopressin secretion, adrenal insufficiency, or compartmental syndrome. In patients with cirrhosis and spontaneous bacterial peritonitis (SBP), early use of antibiotics and intravenous albumin administration decreases the risk for developing renal failure and improves survival. There are no randomized studies that have been specifically performed in patients with cirrhosis and severe sepsis to evaluate treatments that have been shown to improve outcome in patients without cirrhosis who have severe sepsis or septic shock. These treatments include recombinant human activated C protein and protective-ventilation strategy for respiratory failure. Other treatments should be evaluated in the cirrhotic population with severe sepsis including the early use of antibiotics in "non-SBP" infections, vasopressor therapy, hydrocortisone, renal-replacement therapy and liver support systems, and selective decontamination of the digestive tract or oropharynx.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885876     DOI: 10.1002/hep.23264

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  125 in total

1.  Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis.

Authors:  Chalermrat Bunchorntavakul; Disaya Chavalitdhamrong
Journal:  World J Hepatol       Date:  2012-05-27

Review 2.  Bacterial Infection in Patients with Cirrhosis: Don't Get Bugged to Death.

Authors:  Mary D Cannon; Paul Martin; Andres F Carrion
Journal:  Dig Dis Sci       Date:  2020-01       Impact factor: 3.199

3.  Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia.

Authors:  Hyun Park; Ki Jun Jang; Won Jang; Sang Hoon Park; Ji Young Park; Tae Joo Jeon; Tae Hoon Oh; Won Chang Shin; Won-Choong Choi; Dong Hyun Sinn
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

4.  Sepsis in acute on chronic liver failure.

Authors:  Ashish Kumar Jha; Sandeep Nijhawan; Arya Suchismita
Journal:  Dig Dis Sci       Date:  2011-04       Impact factor: 3.199

5.  The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with cirrhosis.

Authors:  Richard Moreau
Journal:  Hepatol Int       Date:  2014-09-06       Impact factor: 6.047

Review 6.  Update on adrenal insufficiency in patients with liver cirrhosis.

Authors:  Anca Trifan; Stefan Chiriac; Carol Stanciu
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 7.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

8.  High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.

Authors:  Puneeta Tandon; Angela Delisle; Jeffrey E Topal; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

9.  Etiology, clinical profile, and inhospital mortality of acute-on-chronic liver failure: a prospective study.

Authors:  Ashish Kumar Jha; Sandeep Nijhawan; Ramesh Roop Rai; Subhash Nepalia; Pankaj Jain; Arya Suchismita
Journal:  Indian J Gastroenterol       Date:  2013-03-23

10.  The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea.

Authors:  M A Aller; I Prieto; S Argudo; F de Vicente; L Santamaría; M P de Miguel; J L Arias; J Arias
Journal:  Int J Inflam       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.